Raffles Medical Group

  • Recommendation: Buy

  • Target price: S$1.15

  • Closing price: S$0.82 (−1.80%)

The group's margins are set to improve as its China operations move towards breaking even on an earnings before interest, tax, depreciation and amortisation (EBITDA) basis.

We forecast double-digit earnings growth for the group from FY2025 to FY2027, with overall healthcare revenue expected to exceed pre-pandemic levels.

In addition, the group's current valuation is attractive, trading below its regional peers. (RHB Securities)

For more information on the Singapore stock market, click here.